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Sheddases are responsible for ectodomain shedding of transmem-
brane proteins, resulting in the release of their extracellular domains
from the cell membrane. Sheddases include members of the
disintegrin and metalloprotease (ADAM) family, such as ADAM10
and ADAM17; aspartyl proteases such as the β-site APP-cleaving
enzymes (BACE1), and matrix metalloproteases (MMPs). ADAM17 (A
Disintegrin and A Metalloproteinase 17; also known as Tumor
necrosis factor-α Converting Enzyme, TACE) was the ﬁrst sheddase
identiﬁed and was initially described to be responsible for releasing
soluble Tumor Necrosis Factor α (TNFα) from the cell membrane
[1,2]. At the moment, more than 30 ADAM17-substrates were
described, among them TNFα and its receptors, some EGF-ligands
and their receptors, Notch, IL15Rα and Interleukin-6 Receptor (IL6R)
[3,4]. Ectodomain shedding has a signiﬁcant impact on the biological
functions of these proteins by converting them from membrane- intosoluble acting molecules. In addition, the loss of receptors from the
cell membrane may lead to the loss of responsiveness of the cells to
their cognate ligands [3,5].
In humans, the soluble IL6R can be generated by alternative
splicing and by ectodomain shedding [6,7]. We have shown
previously that different stimuli such as phorbol 12-mirystate 13-
acetate (PMA), bacterial toxins, bacterial metalloproteinases and
apoptosis led to the cleavage of the IL6R [8–10]. Induced ectodomain
shedding of the IL6R is mainly mediated by ADAM17 and constitutive
shedding is mediated by ADAM10 [11]. Unlike most soluble receptors,
the IL6R does not act as an antagonist, but as an agonist of IL6-
signaling [12]. We now know that the pro-inﬂammatory activities of
IL6 rely mostly on the sIL6R [13–16].
IL6 mediated signals are important for the coordination of the
immune system and IL6 dysregulation can lead to chronic inﬂamma-
tion and cancer development [17,18]. The membrane proteins gp130
and IL6R constitute the signal transducing complex for IL6 stimula-
tion. The agonistic soluble IL6R in complex with IL6 can stimulate cells
only expressing gp130 in a process called IL6-trans-signaling [12].
Sincemost cells of the body do not express themembrane bound IL6R,
most cells are normally not responsive to IL6 alone. IL6-trans-
signaling is important for the regulation of cellular differentiation
and apoptosis and has direct consequences on acute and chronic
inﬂammation and on tumor development. All current data imply that
IL6-trans-signaling but not classic signaling is the main driving force
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bound IL6R might only be responsible for normal homeostasis and
signals via the sIL6R might rather be important during pathophysi-
ological conditions [13–16].
Ectodomain shedding of transmembrane proteins by so-called α-
secretases not only produces extracellular fragments, but also generates
intramembrane/intracellular protein stubs, which initially remain in
the plasmamembrane. Regulated intramembrane proteolysis (RIP)was
described as a process how type I or type II-transmembrane proteins are
proteolytically processedwithin thehydrophobic environment of a lipid
bilayer after ectodomain shedding [20]. Four known classes of
intramembrane cleaving proteases were described: the site-2 protease
(S2P), the signal peptide peptidases (SPP), the rhomboids and the
presenilins (PS, γ-secretase complex). The γ-secretase cleaves the
remaining membrane bound fragment into two peptides, the intracel-
lular domain (ICD) and a small peptide, which is secreted. The γ-
secretase complex composed of several subunits including nicastrin,
APH-1 (anterior pharynx defective 1), PEN-2 (presenilin enhancer-2)
and the catalytically active presenilin (PS) 1 or PS2 [21–23]. γ-secretase
cleaves numerous type I substrates including Notch and theα-Amyloid
Precursor Protein (APP) [21,24,25]. The ectodomain of nicastrin might
bind the newly generated amino terminus of APP and Notch domains
thatwere generated upon ectodomain shedding, thereby recruitingAPP
and Notch intramembrane stubs into the γ-secretase complex [26],
however this view has recently been challenged [27]. Cleavage within
the hydrophobic membranemight be facilitated in an inner-membrane
water-ﬁlled cavity constituted by a hydrophobic pore of two secretase
transmembrane domains [28,29]. In both cases, the intracellular
domains of the substrates are normally released to the cytosol.Whereas
the Notch-ICD mediates signaling, a functional role of the APP-ICD is
currently under debate [21,25]. Since a deﬁnitive biological function
could not be determined for themajority of substrates, the questionwas
raised whether the γ-secretase is the “proteasome of the membrane”
[30].
The IL6R is a substrate of ADAM10 and ADAM17, but the remaining
C-terminal membrane (CTF) stub resulting from ectodomain shed-
ding of the IL6R was not detected and characterized. Here we show
that ADAM10 and ADAM17-mediated cleavage of the IL6R led to CTF
production by γ-secretase cleavage. Importantly, the α-cleavage
preceded the γ-cleavage. Since we did not detect nuclear transloca-
tion of the IL6R-CTF, the γ-cleavage most likely serves to remove the
membrane stub of the IL6R after shedding.
2. Materials and methods
2.1. Cloning procedure
The cDNA for the IL6R-2Z fusion protein was assembled using
splicing by overlapping extension-polymerase chain reaction (SOE-
PCR). The primer pair ProteinA-ovp-up (5′-GACTACTTCTTCCCCA-
GAGTCGAGCTGGTTCCGCGTG-3′) and ProteinA-BamHI-down (5′-
GGATCCTCCCATGGCTACTTTCGGCGCCTGAGCA-3′) was used to amplify
the 2Z cDNA from pQE60–2Z [28]; the primer pair IL6Rup EcoRV (5′
ACTGGATATCGGCTGAACGGTCAAAGACAT-3′) and IL6R-ovp-dn (5′-
CACGCGGAACCAGCTCGACTCTGGGGAAGAAGTAGTC-3′) was used to
amplify the IL6R fragment from p409-IL6R [31]. DNA fragments were
gel puriﬁed, combined and used as a template for ampliﬁcation using
the ﬂanking primers IL6Rup-EcoRV and ProteinA-BamHI-dn. The
resulting 1100 bp product was subcloned into the EcoRV/BamHI
digested pcDNA3.1-IL6R vector. The IL6R-2Z fragment was removed
with SalI andNotI and subcloned into themultiple cloning site of the SalI
andNotI sites of p409. The retroviral expression vector pMOWS-IL6R-2Z
was constructed by insertion of the cDNA coding for the IL6R-2Z fusion
protein into the pMOWS vector. Brieﬂy, the IL6R-2Z fragment was
obtained by digestion of the p409-IL6R-2Z vector with the restriction
enzyme PmeI and puriﬁed by gel extraction. The BamHI/EcoNI digestedpMOWS vector was incubated with DNA-Polymerase I Klenow (large)
fragment to ﬁll in the sticky ends. The PmeI digested IL6R-2Z fragment
was subsequently subcloned into the blunt end opened pMOWS vector.
The cDNA for the IL6R-GFP fusion protein was assembled using SOE-
PCR. The primer pair IL6R-EGFP-up (5′-CAGACTACTTCTTCCCCA-
GAATGGTGAGCAAGGGCGAGGAG-3′) and EGFP-N1-down (5′-
GGCTGATTATGATCTAGAGTCG-3′) was used to amplify the GFP gene
from pEGFP-N1 (Clontech, Palo Alto, USA); the primer pair IL6Rup-
EcoRV (5′-ACTGGATATCGGGCTGAACGGTCAAAGACAT-3′) and EGFP-
IL6R-down (5′-CTCCTCGCCCTTGCTCACCATTCTGGGGAAGAAG-
TAGTCTG-3′) was used to amplify the IL6R fragment from p409-IL6R
[31]. DNA fragmentswere gel puriﬁed, combined andused as a template
for ampliﬁcation using the ﬂanking primers IL6Rup-EcoRV and EGFP-
IL6R-dn. The resulting 500 bp product was subcloned into the EcoRV/
NotI digested pBSK-IL6R vector. After sequencing, the IL6R-GFP
fragment was removed with HindIII and NotI and inserted into the
multiple cloning site of the HindIII/NotI digested pcDNA3.1 vector. The
expression vector pcDNA3.1-IL6R-ICD-GFP was generated by using the
DNA from the pcDNA3.1-IL6R-GFP as a template. The PCR product was
inserted between HindIII and NotI sites of the pcDNA3.1 vector.
The primer pair 1072-ICD-IL6RNotI (5′-GATCGCGGCCGCC-
GATTCTTCTTCAGTACCAC-3′) andEGFP-dn-BamH1(5′-GATCGGATCCT-
TACTTGTACA GCTCGTCC-3′) was used to amplify the IL6R-CTF3-GFP
fragment from pcDNA3.1-IL6R-GFP. The resulting 1050 bp product was
subcloned into the pcDNA3.1 vector by using the restriction sites NotI
and BamHI.
2.2. Reagents
Themetalloprotease inhibitors GI254023X (ADAM10), GW280264X
(ADAM10 and ADAM17) and marimastat were a generous gift from
Glaxo Smith Kline (Stevenage, United Kingdom) [32]. 12-myristate 13-
acetate (PMA), the proteasome inhibitor MG132 and the γ-secretase
inhibitors DAPT (N-[N-(3,5-diﬂuorophenacetyl-L-alanyl)]-S-phenylgly-
cine-t-butyl-ester) and L-685,485 were purchased from Calbiochem
(SchwalbachamTaunus,Germany). ThePKC inhibitorsGF10920X(pan-
PKC inhibitor) and Gö6976 (Ca2+-dependent PKC inhibitor) were
purchased from Sigma-Aldrich (Deisenhofen, Germany). The monoclo-
nal anti-Protein-A antibody was from Sigma-Aldrich (Deisenhofen,
Germany); the polyclonal rabbit anti-phospho-STAT-3 (Tyr-705)
antibody as well as the monoclonal mouse anti-STAT-3 antibody were
purchased from Cell Signalling Technology (Beverly,USA); horseradish
peroxidase-coupled goat anti-rabbit and anti-mouse antibodies were
obtained from Pierce Biotechnology (Rockford, USA). The human IL6R
speciﬁc mAB 14–18 was described elsewhere [15].
2.3. Cell culture
COS-7, HepG2 and HEK293 cells were obtained from the American
Type Culture Collection (Rockville, MD/Manassas, VA, USA). Trans-
fected Ba/F3 cells have been described [13–16]. ADAM17-deﬁcient
and ADAM17-reconstituted mouse embryonal ﬁbroblasts have been
described previously [1]. Phoenix cells were previously described [33].
Murine embryonic ﬁbroblast cell lines deﬁcient for presenilin 1 and 2
(PS1/2) were obtained from Paul Saftig, Institute of Biochemistry,
University of Kiel [34]. All cells were grown in DMEM High Glucose
Culture Medium (PAA Laboratories, Pasching, Austria) supplemented
with 10% fetal calf serum, penicillin (60 mg/l) and streptomycin
(100 mg/l) at 37 °C with 5% CO2 in a humidiﬁed atmosphere.
2.4. Transfection, transduction and selection of cells
HepG2 and COS-7 cells were transiently transfected using DEAE
Dextran as previously described [35]. The transfection efﬁciency as
visualized after 24 h by GFP expression (Axiovert 200 Microscope,
Zeiss) was approximately 60%.
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Transduction of mammalian cells with the retroviral vector pMOWS
was been described previously [33]. Brieﬂy, transfection of the
Phoenix-Eco packaging cell line with pMOWS-IL6R-2Z using Lipofec-
tamin 2000 (Invitrogen, Karlsruhe, Germany) was done according to
the manufacturer's instructions. The cell supernatant containing the
retroviruses was collected 24 h post-transfection and ﬁltered through
a 0.45 µm ﬁlter. For transduction, 500 µl of retroviral supernatant was
supplemented with 1.5 µg/ml polybrene and was added to 1×105
MEF cells and centrifuged at 500×g at room temperature for 2 h.
Afterwards the retroviral supernatantwas removed and replacedwith
standard cell culture medium. For selection of stably transfected MEFs
48 1 h post-transduction 2 µg/ml puromycin was added to the cell
culture medium.
2.5. Immunoblotting and enhanced chemiluminescense (ECL) detection
For Western blotting proteins, separated by SDS-PAGE were
transferred to polyvinylidendiﬂuoride membranes by a semidry
electroblotting procedure. Membranes were blocked in a solution of
TBS (10 mM Tris, pH 8, 150 mM NaCl) supplemented with 0.02%
Tween and 5% skimmed milk powder for at least 1 h, probed with
indicated antibodies overnight at 4 °C, followed by incubation with
horseradish peroxidase-conjugated secondary antibody. Immunore-
active proteins were detected by chemiluminescence using the
enhanced chemiluminescence kit (Amersham Biosciences Inc.)
following the manufacturer's instructions. Signals were quantiﬁed
using the ImageJ software (http://rsbweb.nih.gov/ij/).
2.6. ELISA
IL6R-ELISA was performed as previously described [15]. Microtitre
plates (Greiner Microlon, Solingen, Germany) were coated with anti-
human IL6RMAB227 (R&DSystems,WiesbadenGermany) in PBS. After
blockingwith PBS supplementedwith 5% BSA, 100 µl aliquots of culture
supernatants and standards (rhIL6R; R&D Systems) were added as a
dilution in PBS supplemented with 1% BSA. IL6R bound to the plate
was detected by biotinylated goat anti-human IL6R antibody BAF 227
(R&D Systems) followed by streptavidin-horseradish peroxidase (R&D
Systems). The enzymatic reaction was performed with soluble perox-
idase substrate (BM blue POD from Roche, Mannheim, Germany) at
37 °C and the absorbance was read at 450 nm on a SLT Rainbow plate
reader (Tecan, Maennedorf, Switzerland).
2.7. Membrane preparation and immunoprecipitation
Isolation of cellular membranes and immunoprecipitation of the
IL6R in supernatants and cell lysates followed by Western blotting
was performed as described before [32].
2.8. Immunocytochemistry
HEK293 cells were transfectedwith pcDNA3.1-IL6R-GFP, pcDNA3.1-
IL6R-ICD-GFP or with the control plasmid pcDNA3.1-GFP using
Lipofectamin 2000 (Invitrogen, Karlsruhe, Germany) according to the
manufacturer's instructions. 24 h post-transfection the cells was plated
on polylysine-coated glass coverslips. After 24 h the cells were
stimulated with PMA and afterwards immediately ﬁxed in 4%
paraformaldehyde (Carl Roth, Karlsruhe, Germany) for 15 min at
room temperature. Following two washing steps with PBS, the cells
were permeabilized with PBS containing 0.1% Triton X-100 for 30 min.
After permeabilization, the cells were incubated with DAPI-solution
(50 µg/ml DAPI solved in PBS) for 15 min at room temperature. After
two washing steps, cells were rinsed thoroughly and mounted in slow
Fade anti-Fade medium (Molecular Probes, Göttingen Germany). For
LAMP-1 immunocytochemistry, HEK293 cells were transfected andstimulated as described above and ﬁxed in 4% paraformaldehyde (Carl
Roth, Karlsruhe, Germany) for 15 min at room temperature. Following
two washing steps with PBS, cells were permeabilized with PBS
containing 0.2% saponin for 5 min. After 2 washing steps in PBS, the
cells were incubated in glycine buffer for 10 min (0.2% saponin, 0.12%
glycine in PBS), washed two times in PBS followed by one blocking step
(3% BSA, 0.2% saponin in PBS) for 1 h. Afterwards, cells were incubated
with the rat anti-mouse LAMP-1 antibody (clone 1D4B, Developmental
Studies Hybridoma Bank; Iowa City, IA, USA) in a 1:50 dilution for one
hour in antibody buffer (3% BSA, 0.2% saponin in PBS). Cells were
washed 3 times with PBS and incubated with the Alexa-594
ﬂuorochrom-conjugated secondary anti-mouse antibody (Invitrogen,
Karlsruhe, Germany) in a 1:300 dilution in antibody buffer in the dark.
Afterwards, the cells were washed 3 times and were incubated with
DAPI-solution (50 µg/ml DAPI solved in PBS) for 15 min at room
temperature. After two washing steps in PBS, cells were rinsed
thoroughly and mounted in slow fade anti-Fade medium (Molecular
Probes, Göttingen Germany).
3. Results
3.1. Identiﬁcation of IL6R-2Z derived C-terminal fragments
Since speciﬁc anti-IL6R antibodies could not detect C-terminal IL6R
fragments (CTFs) after PMA-induced shedding (data not shown), we
wanted to develop a cellular assay using C-terminal IL6R fusion
proteins to monitor the generation of C-terminal fragments of the
IL6R in cell lysates of transfected cells after α-secretase cleavage. This
method was successfully employed to detect C-terminal fragments of
amyloid precursor (APP) [36] and APP protein gene family members
APLP-1 and APLP-2 [37] and the membrane bound chemokines
CX3CL1 and CXCL16 [38].
The failure to detect natural IL6R C-terminal fragments might be
due to rapid degradation of IL6R CTFs as a consequence of its small
size. The primary IL6R-CTF after PMA-induced ADAM17-cleavage
between Gln357 und Asp358 [10] would consist of 111 amino acid
residues. Previous reports have documented the usefulness of the 2Z-
tag from Staphylococcus aureus Protein-A and GFP for the character-
ization of CTFs derived by proteolytical processing of the members of
the Amyloid Precursor Protein family [37,39]. 2Z-tagged proteins
could be visualized on immunoblots using anti-Protein-A monoclonal
antibodies. For life cell imaging and to verify the protein cleavage
pattern of IL6R-2Z fusion protein, we generated an IL6R-GFP fusion
protein. The C-terminus of the IL6R was genetically fused to the 2Z
domain of Protein-A consisting of two IgG-binding domains or to GFP
(Fig. 1A). An expression plasmid encoding the IL6R-2Z-cDNA was
transfected in COS7, HepG2 or HEK293-cells to analyze the expression
pattern of IL6R-2Z. As a control, cells transfected with an EGFP-
expression plasmidwere used. Upon PMA treatment, the extracellular
portion of the IL6R-2Z fusion protein or the IL6R-GFP fusion protein
(Fig. 1B) was efﬁciently released from the cell surface. The
extracellular portion of the IL6R-2Z fusion protein together with IL6
was as active as the wild type sIL6R protein in stimulating the
phosphorylation of STAT3 in Ba/F3 cells stably transfected with a
gp130 cDNA (Fig. 1C). In Western blot analysis of cell lysates using an
anti-Protein-A antibody, the full length IL6R-2Z-protein was detected
as a single band with an apparent molecular weight of ∼120 kDa. A
second protein of about 115 kDa likely reﬂects immature IL6R with an
incomplete glycosylation pattern. Four additional proteins in the
molecular range between 40 and 30 kDa were detected, which
probably were CTFs of the IL6R (Fig. 1D, E). No bands were detected
in lysates from the EGFP-transfected control cells (Fig. 1D). When the
same lysates were examined by immunoblotting with themonoclonal
anti-IL6R antibody 14–18, which recognizes an epitope in the
ectodomain of the IL6R, only the ∼120 and 115 kDa bands were
detected in cells transfected with the IL6R-2Z cDNA but not in lysates
Fig. 1. IL6R-derived C-terminal fragments. (A) Schematic representation of the IL6R-2Z and IL6R-GFP fusion proteins. Numbers indicate positions of the ﬁrst amino acid residue for each
domain. (B) HepG2 cells were transiently transfected with expression plasmids coding for IL6R, the fusion protein IL6R-2Z or Hek293 cells were transiently transfected with expression
plasmids coding for the fusion protein IL6R-GFP. The cells transiently transfected with IL6R-2Z cDNA were stimulated with PMA (100 nM) for 2 h or left untreated and cells transiently
transfected with IL6R-GFP cDNA were stimulated with PMA (100 nM) for 30 min or left untreated. The amounts of sIL6R in cell culture supernatants were quantiﬁed by ELISA and
normalized on fold-induction after PMA treatment. (C) HepG2 cells were transiently transfectedwith expression plasmids coding for IL6R or IL6R-2Z. The cells were stimulatedwith PMA
for 2 h or left untreated. The supernatants of HepG2 cells expressing the IL6R or IL6R-2Z were supplemented with 200 ng/ml IL6. After an incubation period of 30 min the supernatants
were used for stimulation of Ba/F3-gp130 cells for 10 min. Ba/F3-gp130 cells were immediately lysed and the proteins were immunoblotted with an anti-P-STAT3 antibody. Re-probing
with an anti-STAT3 speciﬁc antibody conﬁrmed comparable protein loading. (D) HepG2 cells were transiently transfectedwith expression plasmids coding for EGFP or IL6R-2Z. After 48 h
cell lysateswere prepared and analyzed byWestern blotting using anti-Protein-A antibody. (E) COS-7 andHepG2 cells were transiently transfectedwith an expression plasmid coding for
IL6R-2Z. The cells were incubated with or without PMA and analyzed byWestern blotting using anti-Protein-AmAB for detection of full length IL6R-2Z and CTFs thereof. (F) HepG2 cells
were transiently transfected with a plasmid encoding IL6R-GFP (two right lanes) or with a mock plasmid (left lane). After 48 h the cells were stimulated with PMA (100 nM, 2 h). Cell
lysateswere prepared and analyzed byWestern blotting using anti-GFP antibody. (G) HepG2 cells were transiently transfectedwith an expression plasmid coding for IL6R-2Z. Cells were
incubated for 5 min with PMA and then the medium was exchanged against fresh medium lacking PMA. The cells were harvested after indicated time points and analyzed by Western
blotting using anti-Protein-A mAB for detection of CTF3.
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the four smaller fragments detected by the anti-Protein-A antibody
represented IL6R CTFs. We therefore termed the corresponding
polypeptide species as CTF1 (∼40 kDa), CTF2 (∼38 kDa), CTF3
(∼33 kDa) and CTF4 (∼30 kDa). Interestingly, the calculated mass of
the C-terminal IL6R-2Z-fragment occurring after ADAM17-induced
cleavage was calculated to be 32.7 kDa, which closely reﬂects the size
of CTF3 (compare Fig. 1E).
3.2. Induction of CTF3 formation by PMA treatment of cells
It is well established that shedding of the IL6R ectodomain can be
stimulated by the phorbol ester PMA, which exerts its effect via
activation of protein kinase C (PKC). Treatment of cells expressing
IL6R-2Z and IL6R-GFP with 10−7 M PMA led to a massive release of
the sIL6R (Fig. 1B). We therefore reasoned that PMA treatment of cells
transiently transfected with a cDNA coding for IL6R-2Z might
inﬂuence the formation of IL6R derived CTFs. Interestingly, treatment
of HepG2 cells transiently transfected with IL6R-2Z cDNA with PMA
for 2 h selectively increased the level of CTF3 in cell lysates.
Comparable results were also obtained in COS-7 cells transiently
transfected with IL6R-2Z cDNA, thus demonstrating that the observed
induction of CTF3 formation was not cell-type dependent (Fig. 1E).
Experiments with cells transiently transfected with IL6R-GFP cDNA
yielded the same results (Fig. 1F). We also found a slight PMA-
dependent upregulation of CTF1/2 and CTF4 in some experiments as
shown in Fig. 1F. However, this upregulation could not be reproduced
in all experiments. At the moment, we cannot explain the effect of
PMA on the formation of CTF2 and CTF4. The selective induction of
CTF3 by PMA suggested that CTF3 was generated by a protease,
possibly ADAM17, which is responsive to activated PKC and which
was distinct from the protease(s) responsible for the formation of
CTF1, CTF2 and CTF4. The increase of CTF3 was not accompanied by a
reduction in band intensity of the full length IL6R, whichmight be due
to over-expression of IL6R-2Z in the transiently transfected cells.
To assess the kinetics of CTF3-formation following PMA treatment
of cells, IL6R-2Z expressing HepG2 cells were treated with 10−7 M
PMA for 5 min and thereafter the medium was exchanged for fresh
medium lacking PMA. At time points indicated in Fig. 1G, cells were
harvested, lysed and the CTF3 levels were monitored over a period of
8 h by immunoblotting with the anti-Protein-A antibody. A signiﬁcant
increase of the CTF3 fragment intensity was evident already 1 min
after PMA stimulation, reached a maximum between 15 and 30 min
and thereafter decreased to background level after 8 h. This result
indicated that the PMA-induced CTF3 formation is a rapid process,
which might suggest the involvement of the metalloproteinase
ADAM17 [7].
3.3. IL6R-CTF3 is generated by ADAM17
It was shown previously that constitutive cleavage of the IL6R is
mediated by ADAM10, whereas ADAM17 is responsible for PMA-
induced cleavage [11]. HepG2 cells transiently transfected with IL6R-2Z
cDNAwere treatedwith PMA in thepresence of twohydroxamatebased
inhibitors, which were previously demonstrated to differentially block
ADAM10 and ADAM17 [40]. The inhibitor GW280264X (GW) blocked
both, ADAM10 and ADAM17, whereas GI254023X (GI) preferentially
blocked ADAM10 [15,32]. The effect of the broad spectrummetallopro-
teinase inhibitor marimastat on CTF formation was also examined
[15,32]. None of the mentioned inhibitors affected the formation of
CTF1, CTF2 andCTF4 (datanot shown). Asdescribedbefore, treatmentof
the cells with PMA induced the production of CTF3 (Fig. 2A). The
amount of the IL6R-CTF3 fragment was reduced following treatment of
cells with PMA in the presence of the preferential ADAM10-inhibitor
GI254023X (Fig. 2A) whereas the ADAM10/17 inhibitor GW280264X
completely blocked the formation of CTF3, thus conﬁrming that thisfragment is generated with the help of ADAM17 (Fig. 2A). The IL6R-
cleavage site used by the protease ADAM10 has not been deﬁned at the
molecular level; since both inhibitors suppressed the formation of the
same CTF, our results indicate that ADAM17 and ADAM10 use the same
or adjacent cleavage sites within the IL6R.
Examination of corresponding conditioned media conﬁrmed that
GW280264X suppressed PMA induced release of the IL6R ectodomain
into the cell culturemedium, whereas only aminor inhibition of PMA-
induced IL6R-2Z shedding was seen after treatment with the
preferential ADAM10 inhibitor GI254023X (Fig. 2B). Of note, none of
the inhibitors inﬂuenced the levels of CTF1, CTF2 and CTF4, raising the
question whether these proteins might reﬂect unspeciﬁc degradation
products of the IL6R-2Z-fusion protein (data not shown and Fig. 4D).
Next, we used ADAM17-deﬁcient murine embryonic ﬁbroblasts
(MEFs) and ADAM17-deﬁcient MEFs reconstituted with a cDNA coding
for ADAM17. These cells were retrovirally transduced with an IL6R-2Z-
cDNA and were treated with PMA for 2 h or were left untreated. PMA-
induced shedding of the IL6R was almost completely abolished in
ADAM17-deﬁcient MEFs, whereas the ADAM17-reconstituted MEFs
displayed normal PMA-induced IL6R shedding (Fig. 2C). As depicted in
Fig. 2D, CTF3 could only be detected in MEFs reconstituted with an
ADAM17 cDNA but not in ADAM17-deﬁcient MEFs. Interestingly, the
overall occurrence of CTF1/2 (one band) but not of CTF4was reduced in
the ADAM17-deﬁcientMEFs as compared to the ADAM17 reconstituted
MEFs in the presence and absence of PMA. The different CTF1/2 levels
could be related to the independent clonal origin of the MEFs.
Importantly, even though full length IL6R protein could be detected in
both cell lines at comparable amounts, no CTF3 could be detected after
PMA stimulation in the absence of ADAM17, indicating that CTF3 is
generated by ADAM17-mediated cleavage of the IL6R-2Z protein. Since
the PMA-stimulated generation of CTF3was transient and the detection
level varied in different cell lines, we concluded that CTF3 was rapidly
degraded after generation.
3.4. Ca2+-dependent PKCs are involved in the PMA-induced CTF3
generation
PMA-induced ectodomain shedding of diverse membrane proteins
such as IL6R is induced via activation of protein kinases of the PKC
family. Using the PKC inhibitors GF109203X and Gö6976 we analyzed
whether members of the PKC family are involved in the PMA-elicited
increase in CTF3 formation. HepG2 cells transiently transfected with
the IL6R-2Z-cDNA were treated with the PKC inhibitors alone or in
combination with PMA and the formation of the IL6R-2Z derived CTF3
was examined by immunoblotting (Fig. 2E). PMA-induced CTF3
formation was suppressed by the pan-PKC kinase inhibitor
GF109203X and the inhibitor of Ca2+-dependent PKC isoenzymes
Gö6976. Examination of sIL6R levels in conditioned medium with an
antibody recognizing an epitope in the ectodomain of sIL6R conﬁrmed
that the PMA-induced release of the sIL6R was suppressed in the
presence of both inhibitors (Fig. 2E). Thus, this experiment suggested
the involvement of Ca2+-dependent PKC isoenzymes as mediators of
PMA-induced stimulation of IL6R-CTF3 formation.
3.5. The CTF3 of IL6R is a substrate of the γ-secretase
Regulated intramembrane proteolysis is a process, by which
transmembrane proteins are proteolytically cleaved within their
transmembrane domains by a protease complex termed γ-secretase
usually preceded by an α-secretase (ADAM10 or ADAM17) mediated
cleavage within the ectodomain. This process leads to the generation of
intracellular domains (ICDs) from the previously generated C-terminal
fragments (CTFs). DAPT (N-[N-(3,5-diﬂuorophenacetyl)-L-alanyl]-S-
phenylglycine-t-butyl-ester) was described to inhibit γ-secretase
activity via binding to the C-terminal fragment of presenilin [41].
To address whether the IL6R represents a novel substrate for the γ-
Fig. 2. CTF3 is generated by ADAM17 after PMA treatment. (A) HepG2 cells were transiently transfected with an expression plasmid coding for IL6R-2Z and stimulated for 2 h with
and without PMA (100 nM) in the presence and absence of the protease inhibitors GW280264X (GW, 3 µM) and GI254023X (GI, 3 µM). Cells were harvested and analyzed by
Western blotting using anti-Protein-A mAB for detection of CTF3. (B) HepG2 cells were transiently transfected with an expression plasmid coding for IL6R-2Z and stimulated for 2 h
with and without PMA in the presence and absence of the protease inhibitors GW280264X (GW) and GI254023X (GI). The sIL6R protein in the culture media was quantiﬁed using a
sIL6R-speciﬁc ELISA. (C) IL6R-2Z-cDNA retrovirally transduced ADAM17-deﬁcient MEFs and reconstituted MEFs were treated with PMA for 2 h. The sIL6R protein in the culture
media was quantiﬁed using a sIL6R-speciﬁc ELISA. (D) IL6R-2Z-cDNA-stably transduced ADAM17-deﬁcient MEFs and reconstituted MEFs were treated with PMA for 2 h. The
occurrence of IL6R-CTF3 in cell lysates was assessed by Western blotting using anti-Protein-A mAB. (E) HepG2 cells were transiently transfected with an expression plasmid coding
for IL6R-2Z and stimulated for 2 h with and without PMA in the presence and absence of the PKC inhibitors GF109203X (GF, 5 µM) and Gö6976 (Gö, 1 µM). The cells were harvested
and analyzed byWestern blotting using anti-Protein-A mAB for detection of CTF3. The sIL6R protein in the culture media was immunoprecipitated and analyzed byWestern blotting
using anti-IL6R mAB for detection of sIL6R.
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cDNA were treated with DAPT in a dose-dependent manner over a
concentration range of 0.1 to 10 µMDAPT in the presence or absence of
PMA and cell lysates were examined by immunoblotting (Fig. 3A).
Whereas PMA treatment alone only led to a faint CTF3 protein fragment
formation, combined treatment with PMA and DAPT resulted in
considerably more CTF3 formation. The results were quantiﬁed by
density calculation of CTF3 using the ImageJ software. A dose-
dependent PMA-dependent and independent increase of CTF3 became
apparent already after the treatment of the cells with 0.1 µM DAPT,
however this effect was maximal after treatment of the cells with 5–
10 µM DAPT.
Additionally, we have used the γ-secretase inhibitor L-685,485.
Dose–response experiments were performed from 0.1 µM to 5 µM L-
685,485 (Fig. 3B). The results were quantiﬁed by density calculation of
CTF3 using the imageJ software. A dose-dependent increase of CTF3
became apparent already after the treatment of the cells with 0.5 µM
L-685,485, however this effect was maximal after treatment of the
cells with 5 µM L-685,485.
Next, ADAM17-deﬁcient MEFs and ADAM17-reconstituted MEFs
retrovirally transduced with IL6R-2Z cDNAwere treated with DAPT in
the presence or absence of PMA for 2 h. Again, CTF3 speciﬁcally
accumulated in PMA treated ADAM17-reconstituted MEFs but not in
ADAM17-deﬁcient MEFs. Accumulation of CTF3 was further increased
by combined PMA and DAPT treatment in ADAM17-reconstituted
MEFs and in ADAM17 deﬁcient MEFs, indicating that processing of
CTF3 is mediated by the γ-secretase complex (Fig. 3C). The minor
accumulation of the CTF3 after PMA and DAPT treatment in the
ADAM17-deﬁcient MEFs indicated that CTF3 generated by otherproteases such as ADAM10 was also a substrate of the γ-secretase
complex. We detected an increased intensity of the CTF4 fragment
(Fig. 3A, B and C), which might indicate that also CTF4 is a substrate of
the γ-secretase. Since the increase in CTF4 was not seen in all
experiments, we cannot exclude that CTF4 might reﬂect an unspeciﬁc
degradation product of the IL6R-2Z-fusion protein.
To further corroborate that the PMA-induced CTF3 of the IL6R is a
novel substrate of the γ-secretase complex, we used MEFs deﬁcient in
the catalytically active γ-secretase subunits presenilin (PS)1 and PS2,
which were transduced with IL6R-2Z cDNA. Although wild type MEFs
showed less expression of the IL6R-2Z protein as compared to the
PS1/PS2-deﬁcient MEFs, the ratio of the secreted IL6R after PMA
stimulation showed only minor differences between both cell types,
indicating that α-secretase cleavage is not affected by γ-secretase
deﬁciency (Fig. 4A). Next, we investigated the cell lysates for the
presence of IL6R fragments. Again, PMA-induced CTF3 formation was
only faintly visible in wild type cells whereas a predominant band
corresponding to CTF3 was detected in PS1/PS2-deﬁcient MEFs
(Fig. 4B). Taken together these data showed that the IL6R-CTF3 is a
novel substrate of γ-secretase-mediated regulated intramembrane
proteolysis.
To further conﬁrm the effect of γ-secretase inhibition on the fate of
the IL6R, HepG2-cells transiently transfected with IL6R-2Z cDNAwere
treated with PMA in the presence or absence of DAPT. The cells were
lysed and divided into membrane and cytosolic fractions (Fig. 4C). No
CTF3-fragment could be detected in the cytosolic fraction. As
expected, all IL6R-CTFs including CTF3 were found in the membrane
fraction, at least until cleavage by the γ-secretase had occurred
(Figs. 4C and 5B). The cleavage of the IL6R by ADAM10/17 occurred in
Fig. 3. Inhibition of γ-secretase activity leads to accumulation of IL6R-CTF3. (A) HepG2
cells were transiently transfected with an expression plasmid coding for IL6R-2Z and
stimulated for 24 h with increasing concentrations of the γ-secretase inhibitor DAPT
(0.1–10 µM, as indicated). PMA was added for the last two hours of DAPT treatment.
Cells were harvested and analyzed byWestern blotting using anti-Protein-A. (B) HepG2
cells were transfected as described in (A) and stimulated for 24 h with increasing
concentrations of the γ-secretase inhibitor L-685,458 (0.1–5 µM, as indicated). PMA
was added for the last two hours of L-685,458 treatment. Cells were harvested and
analyzed by Western blotting using anti-Protein-A. (C) ADAM17-deﬁcient MEFs and
reconstituted MEFs, stably transduced with IL6R-2Z-cDNA were treated with PMA for
2 h in the presence or absence of the γ-secretase inhibitor DAPT (10 µM). The
occurrence of CTF3 was assessed by Western blotting using anti-Protein-A mAb.
Fig. 4. Accumulation of IL6R-CTF3 in γ-secretase deﬁcient cells. (A) PS1/2-deﬁcient MEFs
and reconstitutedMEFs, stably transducedwith IL6R-2Z-cDNAwere treatedwith PMA for
2 h. Theoccurrenceof sIL6RwasassessedbyELISA. (B) PS1/2-deﬁcientMEFs andwild type
(WT) MEFs, stably transduced with IL6R-2Z-cDNA were treated with PMA for 2 h. The
occurrence of CTF3 was assessed by Western blotting using anti-Protein-A mAB.
(C) HepG2 cells were transiently transfected with an expression plasmid coding for
IL6R-2Z and were treated with PMA for 2 h in the presence or absence of the γ-secretase
inhibitor DAPT. The occurrence of CTF3 in the membrane [m] or cytosolic [c] fraction was
assessed byWestern blotting using anti-Protein-AmAB. (D) HepG2 cells were transiently
transfected with an expression plasmid coding for IL6R-2Z and stimulated for 24 h with
andwithout the proteosome inhibitorsMG132 (MG, 2.5 µM), lactacystin (L, 15 µM) or the
metalloprotease inhibitors GW280264X (GW, 3 µM) and GI254023X (GI, 3 µM). The
occurrence of the IL6R fusion proteinwas assessed byWestern blotting using anti-Protein-
A mAB.
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transmembrane region and the expected cleavage site of the γ-
secretase would be within the transmembrane region of IL6R. It is
generally assumed that the ICD of a γ-secretase substrate is 2–3 kDa
smaller than its CTF andmight be released into the cytoplasmwhere it
is either transported into the nucleus or rapidly degraded by the
proteasome [42,43]. Therefore, the ICD of IL6R-CTF3 would have an
Fig. 5. IL6R-derived CTF3 is processed by γ-secretase at the plasma membrane and in endosomal compartments. (A) HEK293 cells were transiently transfected with an expression
plasmid coding for IL6R-GFPandpulse-stimulated for 5 minwithPMA,washedand incubated incell culturemedium for the indicated timepoints. Cellswereﬁxed in4%paraformaldehyde,
permeabilized with PBS containing 0.1% Triton-X100 and GFP-ﬂuorescence was analyzed using the ﬂuorescence microscope Zeiss Axiovert 200M. The nuclei were visualized by
DAPI staining; a–f: IL6R-GFP staining, g–l: IL6R-GFP andDAPI staining. (B) HEK293 cellswere transiently transfectedwith an expressionplasmid coding for IL6R-GFP and pulse-stimulated
for 5 min with PMA in the presence and absence of the protease inhibitor GW280264X (3 µM) and the γ-secretase inhibitor DAPT (10 µM). Cells were washed and incubated in
cell culture medium for additional 30 min in the presence and absence of the inhibitors. Cells were ﬁxed in 4% paraformaldehyde, permeabilized with PBS containing 0.1% Triton-X100
and GFP-ﬂuorescence was analyzed using the Fluorescence microscope Zeiss Axiovert 200M. The nuclei were visualized by DAPI staining. (C) HEK293 cells were transiently transfected
with an expression plasmid coding for the full length IL6R-GFP or an expression plasmid coding for the IL6R-ICD-GFP or GFP alone. After transfection the cells were stimulated for 30 min
with PMA (100 nM) or left untreated. The nuclear export inhibitor Leptomycin B (40 nM)was added 4 h prior to PMA stimulation. Cells were prepared and additionally stainedwith DAPI
and for LAMP1.
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the CTF4 band. Indeed, in some experiments (Fig. 3A and B) we could
detect an increased intensity of the CTF4 fragment. We also were not
able to detect a cytosolic IL6R-ICD in the soluble fraction.
To characterize the degradation pathway involved in the clearance
of the IL6R-CTF3/ICD we incubated IL6R-2Z overexpressing HepG2
cells for 24 h with two different proteasome inhibitors. The widely
used compound MG132 blocks the proteasome and additional
proteases like the lysosomal cathepsins and non-lysosomal calpains[44]. Lactacystin is supposed to be a speciﬁc proteasome inhibitor.
Treatment of HepG2 cells with MG132 led to a strong accumulation of
the full length IL6R-2Z fusion protein as well as CTF1 and CTF3. In
contrast, we did not observe such an accumulation by treating the
cells with the more speciﬁc proteasome inhibitor lactacystin indicat-
ing that the proteasome is not involved in the degradation process of
the IL6R CTFs (Fig. 4D).We conclude from these experiments showing
that blockade of γ-secretase led to a strong accumulation of IL6R-CTF3
that IL6R-CTF3 is processed by γ-secretase.
Fig. 6. γ-secretase cleavage product of IL6R is located in endosomal structures. HEK293
cells were transiently transfected with an expression plasmid coding for the IL6R-GFP.
After transfection the cells were left untreated or stimulated for 30 minwith 100 nMPMA.
Cells were ﬁxed in 4% paraformaldehyde and stained with DAPI and for LAMP1. GFP- and
LAMP1-ﬂuorescence was analyzed using the ﬂuorescence microscope Zeiss Axiovert
200M. a–d: GFP staining; e–h: LAMP-1 staining; i–l: merged images. The higher
magniﬁcation images (b, d) show GFP-ﬂuorescence and LAMP1 ﬂuorescence (f, h)
whereas the images (j, l) depict the co-localization of the γ-secretase cleavage product of
IL6R-GFP and LAMP-1 in yellow.
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We used HEK293-cells transiently transfected with the GFP-
tagged IL6R-GFP cDNA tomonitor IL6R processing by cellular imaging.
The cells were pulse-treated with PMA for 5 min, and occurrence of
GFP-ﬂuorescence was monitored for 720 min. Since we previously
showed that CTF3 generation was maximal 30–60 min after PMA
treatment (Fig. 1G), we decided to use the 30 min time point to follow
the fate of IL6R-CTF. The IL6R-GFP fusion protein could be clearly
detected at the cell membrane with some GFP-ﬂuorescence being
localized in endosomal compartments (Fig. 5A). Nuclei were stained
with DAPI to illustrate that the IL6R-CTFs were not accumulating
within the nucleus. Almost all ﬂuorescence disappeared from the cell
membrane 30 min after the PMA-pulse and it took 360 min for the
IL6R-GFP to be re-expressed at the cell membrane. Fig. 5B shows that
the loss of PMA-induced IL6R-GFP-ﬂuorescence from the cell surface
was blocked by the ADAM10/ADAM17 speciﬁc inhibitor GW280264X,
indicating that the disappearance of GFP-ﬂuorescence from the
plasma membrane was initiated by ADAM17-mediated ectodomain
shedding of the IL6R.
It was previously shown that γ-secretase may cleave its substrates
at the plasma membrane as well as in endosomal vesicles, but not in
the ER, the Golgi and in constitutive secretory vesicles [39]. Therefore,
HEK293-cells transiently transfected with IL6R-GFP cDNA were
treated with PMA in the presence of the γ-secretase inhibitor DAPT
(Fig. 5B). Even though ADAM17-mediated ectodomain shedding of
the IL6R occurred normally (also compare Fig. 4A), in the presence of
DAPT, the IL6R-GFP-ﬂuorescence did not disappear from the cell
membrane.
Furthermore, we investigated whether the γ-secretase cleavage
product of IL6R translocated to the nucleus.We stimulatedHEK293 cells
transiently transfected with the full length IL6R-GFP cDNAwith PMA in
the presence of Leptomycin B (LMB), which is an inhibitor of nuclear
export. Neither PMA alone or combined PMA and LMB treatment led to
visible accumulation of the IL6R-CTF in the nucleus as judged by
ﬂuorescence microscopy and DAPI co-staining. Instead, we noted that
the GFP-ﬂuorescence after PMA treatment was shifted from the plasma
membrane to intracellular structures, probably endosomal vesicles,
indicating that the unidentiﬁed γ-secretase cleavage product of IL6R
remained associated with membraneous structures (Fig. 5C). We
genetically engineered a GFP-tagged IL6R-ICD cDNA, which codes for
the complete intracellular domain of the IL6R without the transmem-
brane domain.We then analyzed whether this fragment corresponding
to the complete intracellular domain of the IL6R is also associated with
endosomal/lysosomal compartments. HEK293 cells were transiently
transfected with this GFP-tagged IL6R-ICD cDNA and GFP-ﬂuorescence
was analyzed by ﬂuorescence microscopy with and without DAPI co-
staining. As shown in Fig. 5C, the GFP-tagged IL6R-ICD was mainly
detected in the cytosol, but not in endosomal/lysosomal compartments
and therefore resembled the situation in cells thatwere transfectedwith
GFP alone (Fig. 5C, right panel). Treatment of these cells with
Leptomycin B also did not lead to an accumulation of the IL6R-ICD-
GFP in the nucleus. These experiments indicate that IL6R-ICD was not
transported to the nucleus. As a control, cells were stained for the late
endosomal/lysosomal marker LAMP-1 (see below).
To identify the nature of the GFP-ﬂuorescence containing
structures, we treated IL6R-GFP overexpressing HEK293 cells with
or without PMA and again stained the cells for LAMP-1 (Fig. 6). Under
both conditions we found co-localization of IL6R-GFP within the same
endosomal structure as the lysosomal protein LAMP-1, which appear
in yellow. However, in PMA treated cells we found more co-
localization signals within intracellular compartments than in
untreated cells (Fig. 6j, l). The increase of these vesicles happened at
the same time when IL6R-CTF3 was generated and further processed
by the γ-secretase suggesting that these intracellular compartments
are ﬁlled with IL6R-CTFs and cleavage products thereof.3.7. Expression of IL6R-CTF3 leads to intravesicular localization
To analyze, whether the ADAM17-dependent increase of intracel-
lular staining in IL6R-GFP transfected cells might be caused by the
generation and processing of IL6R-CTF3, we have generated a CTF3-
mimicking protein. This fusion proteinwas named IL6R-CTF3-GFP and
contained the IL6R signal peptide followed by a c-myc-tag and the C-
terminal fragment starting with asp 358 of the human IL6R (Fig. 7A).
ADAM17 cleaves the IL6R between gln 357 and asp 358 [10], the
natural remaining IL6R cleavage product starts with asp 358.
Therefore this construct mimics the IL6R-C-terminal fragment after
ADAM17-mediated cleavage. The cDNA coding for IL6R-CTF3-GFPwas
transiently transfected in HEK293 cells. Upon transfection, the IL6R-
CTF3-GFP fusion protein was detected as a 37 kDa band upon SDS-
PAGE and Western blotting (data not shown). We performed
ﬂuorescencemicroscopyusing this fusionproteinunder non-stimulated
and PMA-stimulated conditions (Fig. 7B). In transfected cells the fusion
protein was localized intracellularly and associated with intracellular
membrane structures. LocalizationofGFP-ﬂuorescencewas reminiscent
of the GFP-ﬂuorescence of the full length IL6R after PMA-stimulated
cleavage. This situation did not change after PMA stimulation of IL6R-
CTF3-GFP expressing cells. The higher magniﬁcation images show co-
localization of GFP and LAMP-1 in some vesicles of untreated and PMA
treated cells. This situation did not change upon treatment of the
transfected cells with Leptomycin B (right panels). These data
demonstrate that in most cells an IL6R-CTF3 mimicking fusion protein
was translocated to intracellular vesicles. It is noteworthy, that the IL6R-
CTF3-GFP protein without PMA treatment shows a similar intracellular
behavior as the cleaved IL6R-GFP fusion protein upon PMA stimulation
of the cells, underlining the fact that this protein construct mimics the
cleaved membrane C-terminal fragment of the shed IL6R.
4. Discussion
The IL6R exists as a transmembrane and soluble protein. The human
sIL6R can be generated by alternative splicing and ectodomain shedding
Fig. 7. IL6R-CTF3 is located in endosomal structures. (A) Schematic representation of the IL6R-CTF3-GFP fusion protein. (B) HEK293 cells were transiently transfected with an
expression plasmid coding for IL6R-CTF3-GFP. After 48 h, cells were stimulated for 30 min with PMA or left untreated. The nuclear export inhibitor Leptomycin B (40 nM) was added
4 h prior to PMA stimulation. Cells were ﬁxed in 4% paraformaldehyde. GFP-ﬂuorescence as well as LAMP-1 and DAPI ﬂuorescence was analyzed using ﬂuorescence microscopy. The
higher magniﬁcation images show the co-localization of IL6R-CTF3 and LAMP-1 in yellow.
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mechanism for the generation of the sIL6R protein [6,7,45]. The sIL6R in
combination with IL6 can activate cells that do not express membrane
bound IL6R but the receptor chain gp130, which is ubiquitously
expressed. This processwas named IL6-trans-signaling and is important
for cellular activation and differentiation [12]. It has been shown that
IL6-trans-signaling but not IL6-classic signaling via the membrane
bound IL6R is themain driving force of chronic inﬂammatory states like
rheumatoid arthritis and Crohn's disease [19].
Nothing is known about the fate of the C-terminal part of the IL6R,
which remains in the membrane after ectodomain shedding. In
previous studies we and others demonstrated that in a slow process
the IL6R is constitutively released by ADAM10, whereas inducible
release triggered e.g. by PMA is a fast process mediated by ADAM17.
Sheddases such as ADAM10 and ADAM17 can act in combination with
γ-secretase to perform regulated intramembrane proteolysis of the
remaining membrane-associated protein and release of ICD. Gener-
ation of ICDs followed a speciﬁc sequence of proteolytic steps inwhich
ectodomain shedding of the substrate must occur before regulated
intramembrane proteolysis of ICD [46].A number of proteins have been shown to undergo intramem-
brane proteolysis, including the members of the Amyloid Precursor
Protein (APP) family, the receptor tyrosine kinase ErbB4, the low-
density lipoprotein receptor-related protein (LRP) and the cell
adhesion molecules cadherin, CD44 and Notch [47].
In this study we characterized for the ﬁrst time regulated
intramembrane proteolysis of the human IL6R. Cleavage by
ADAM17 resulted in the generation of a major 65 kDa soluble IL6R
fragment, but the CTF-fragments of the IL6R could not be detected in
cell lysateswith an antibody speciﬁcally directed against the C-terminus
of the IL6R. Therefore we decided to construct two C-terminal
IL6R fusion proteins IL6R-2Z and IL6R-GFP. 2Z- and GFP fusion proteins
were successfully used for the identiﬁcation and characterization of the
CTFs of the type I-transmembrane proteins APP, Notch and APLP1 [39].
Using anti-2Z- and anti-GFP-speciﬁc antibodies, four IL6R-CTFs were
detected. Activation of ADAM17 resulted in strongaccumulation of CTF3
at cellular membranes and in a simultaneous release of the IL6R-
ectodomain. The generation of CTF3 was almost absent in ADAM17-
deﬁcient MEFs, which support the ﬁnding that CTF3 is generated by
ADAM17. The cleavage pattern observed for IL6R-2Z and IL6R-GFPwere
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affected by the treatments or in any cell line used in our study. Therefore
we concluded that the formation of CTF1, 2 and CTF4 was not related to
ADAM17-mediated shedding of the IL6R and was not subject to γ-
secretase cleavage.
Furthermore, we showed that γ-secretase inactivation by inhibi-
tors or the absence of γ-secretase in presenilin 1/2-deﬁcient mouse
embryonic ﬁbroblasts resulted in accumulation of CTF3 after PMA
stimulation, indicating that only CTF3 was a substrate of the γ-
secretase complex. Again CTF1, 2 and 4 were not affected. The
remaining IL6R-ICD, which is a product of γ-secretase cleavage of
CTF3, could not be detected either in the cytosolic or in the membrane
fraction of transiently and stably transfected cells. Proteolytic
processing of transmembrane proteins is often linked with the release
of an ICD into the cytosol which regulates signaling functions of the
receptor. Thus, Notch-ICD is known to recruit histone acetyl
transferases and RBP-J/CBF-1 to activate gene transcription [48]. In
this study we provide experimental evidence for a novel pathway
involved in CTF sorting. Even though, we were not able to physically
detect an IL6R-ICD, we clearly see a translocation of IL6R-GFP-
ﬂuorescence into endosomal compartments after ADAM and γ-
secretase mediated cleavage of the IL6R. Therefore we conclude that
the γ-secretase cleavage product of IL6R remained associated with the
plasma membrane before it was internalized and transported into
endosomal vesicles. A construct, which contained the complete
intracellular domain but not the transmembrane domain of the IL6R
fused to a GFP-portion (IL6R-ICD-GFP) was not associated with
endosomal/lysosomal vesicles. The ﬂuorescence microscopy data
support our assumption that after being internalized in endosomal
vesicles ICD-GFP might be sorted into internal luminal vesicles of the
late endosome. Recently, itwas reported, that the cytoplasmic portion of
the type I-transmembrane protein HB-EGF after proteolytic processing
by ADAMproteases can be transferred to the inner nuclear envelope via
endocytosis and early endosomes. A transmembrane-free HB-EGF has
never been detected and a membrane bound HB-EGF-cytosolic
fragment is a major product after shedding stimuli [49,50].
The endosomal compartments containing the IL6R-ICD-GFP might
later fuse with lysosomes where the IL6R-ICD-GFP might be degraded
by lysosomal enzymes like cathepsins. However, at this stage, we have
not identiﬁed the IL6R-ICD nor the proteases involved in IL6R-ICD
degradation.
So far,we have not identiﬁed a physiological role of the IL6R-CTF3. In
case of the chemokines CX3CL1 and CXCL16, regulated intramembra-
neous proteolysis most likely serves as a mechanism to clear the cell
membrane from the C-terminal fragments [30]. At the moment, we
believe in a similar role of the proteolysis of the IL6R-CTF3 by γ-
secretase. Since we did not observe IL6R-ICD-GFP-ﬂuorescence within
the nucleus, even in the presence of the nuclear export inhibitor
Leptomycin B, the IL6R-ICD is most likely not transported into the
nucleus and thereforemight not be directly involved in gene regulation.
Interestingly it was shown that the IL6R-ICD mediates the
basolateral sorting of the IL6R in polarized cells. At the present it is
unclear, how the cleavage of the IL6R by ADAM17 and its subsequent
processing by the γ-secretase interferes with this sorting process and
whether and how these processes are coordinatedwithin the cell [51].
It is conceivable that proteolytic processing of the IL6R by γ-secretase,
precludes binding to proteins of the intracellular sorting machinery
and thereby inﬂuences sorting of other proteins.
Taken together, our data demonstrate, that the IL6R is rapidly
processed by subsequent cleavages mediated by the ADAM17
metalloprotease and γ-secretase, both occurring at the plasma
membrane and that this process results in the release of the sIL6R
and the degradation of the ADAM17-related C-terminal fragment of
the IL6R in intracellular compartments. At the moment we have no
indication that a potential IL6R-ICD plays an additional intracellular
role before degradation.Acknowledgements
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